Eli Lilly and Company LLY.MX Stock
Eli Lilly and Company Price Chart
Eli Lilly and Company LLY.MX Financial and Trading Overview
Eli Lilly and Company stock price | 12662.38 MXN |
Previous Close | 9836 MXN |
Open | 9835.99 MXN |
Bid | 9740.06 MXN x 100 |
Ask | 9874.29 MXN x 10000 |
Day's Range | 9835.99 - 9845 MXN |
52 Week Range | 5634.99 - 11109.96 MXN |
Volume | 759 MXN |
Avg. Volume | 227 MXN |
Market Cap | 9.35T MXN |
Beta (5Y Monthly) | 0.331 |
PE Ratio (TTM) | 104.16887 |
EPS (TTM) | 94.97 MXN |
Forward Dividend & Yield | 89.92 (0.91%) |
Ex-Dividend Date | February 14, 2024 |
1y Target Est | N/A |
LLY.MX Valuation Measures
Enterprise Value | 8.87T MXN |
Trailing P/E | 104.16887 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 291.40002 |
Price/Book (mrq) | 789.0518 |
Enterprise Value/Revenue | 276.607 |
Enterprise Value/EBITDA | 783.955 |
Trading Information
Eli Lilly and Company Stock Price History
Beta (5Y Monthly) | 0.331 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 11109.96 MXN |
52 Week Low | 5634.99 MXN |
50-Day Moving Average | 10378.79 MXN |
200-Day Moving Average | 8517.77 MXN |
LLY.MX Share Statistics
Avg. Volume (3 month) | 227 MXN |
Avg. Daily Volume (10-Days) | 233 MXN |
Shares Outstanding | 949.31M |
Float | 897.74M |
Short Ratio | N/A |
% Held by Insiders | 0.15% |
% Held by Institutions | 84.37% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 4.37 |
Trailing Annual Dividend Yield | 0.044% |
5 Year Average Dividend Yield | 154.00% |
Payout Ratio | 0.7917 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | September 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 15.55% |
Operating Margin (ttm) | 37.27% |
Gross Margin | 78.66% |
EBITDA Margin | 35.28% |
Management Effectiveness
Return on Assets (ttm) | 11.62% |
Return on Equity (ttm) | 46.46% |
Income Statement
Revenue (ttm) | 32.07B MXN |
Revenue Per Share (ttm) | 35.62 MXN |
Quarterly Revenue Growth (yoy) | 36.79% |
Gross Profit (ttm) | 21.91B MXN |
EBITDA | 11.32B MXN |
Net Income Avi to Common (ttm) | 4.99B MXN |
Diluted EPS (ttm) | 94.51 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.62B MXN |
Total Cash Per Share (mrq) | 2.92 MXN |
Total Debt (mrq) | 20.33B MXN |
Total Debt/Equity (mrq) | 179.81 MXN |
Current Ratio (mrq) | 1.046 |
Book Value Per Share (mrq) | 12.477 |
Cash Flow Statement
Operating Cash Flow (ttm) | 5.71B MXN |
Levered Free Cash Flow (ttm) | 3.9B MXN |
Profile of Eli Lilly and Company
Country | Mexico |
State | IN |
City | Indianapolis |
Address | Lilly Corporate Center |
ZIP | 46285 |
Phone | 317 276 2000 |
Website | https://www.lilly.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 39000 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Q&A For Eli Lilly and Company Stock
What is a current LLY.MX stock price?
Eli Lilly and Company LLY.MX stock price today per share is 12662.38 MXN.
How to purchase Eli Lilly and Company stock?
You can buy LLY.MX shares on the Mexico exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eli Lilly and Company?
The stock symbol or ticker of Eli Lilly and Company is LLY.MX.
Which industry does the Eli Lilly and Company company belong to?
The Eli Lilly and Company industry is Drug Manufacturers-General.
How many shares does Eli Lilly and Company have in circulation?
The max supply of Eli Lilly and Company shares is 950.77M.
What is Eli Lilly and Company Price to Earnings Ratio (PE Ratio)?
Eli Lilly and Company PE Ratio is 133.33030000 now.
What was Eli Lilly and Company earnings per share over the trailing 12 months (TTM)?
Eli Lilly and Company EPS is 94.97 MXN over the trailing 12 months.
Which sector does the Eli Lilly and Company company belong to?
The Eli Lilly and Company sector is Healthcare.